Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.0860
+0.0130 (17.81%)
At close: Dec 5, 2025
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
794.83K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Mid-Atlantic Home Health Network | 27.00M |
Bio-Path Holdings News
- 6 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 - Newsfile Corp
- 6 months ago - Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewsWire
- 7 months ago - Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - GlobeNewsWire
- 7 months ago - Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 9 months ago - Bio-Path GAAP EPS of -$4.12 - Seeking Alpha
- 9 months ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 9 months ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 10 months ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus